000144659 001__ 144659
000144659 005__ 20240229105156.0
000144659 0247_ $$2doi$$a10.18632/oncotarget.26370
000144659 0247_ $$2pmid$$apmid:30559935
000144659 0247_ $$2pmc$$apmc:PMC6284855
000144659 0247_ $$2altmetric$$aaltmetric:70419757
000144659 037__ $$aDKFZ-2019-02101
000144659 041__ $$aeng
000144659 082__ $$a610
000144659 1001_ $$aRogers, Hazel Anne$$b0
000144659 245__ $$aLimitations of current in vitro models for testing the clinical potential of epigenetic inhibitors for treatment of pediatric ependymoma.
000144659 260__ $$a[S.l.]$$bImpact Journals LLC$$c2018
000144659 3367_ $$2DRIVER$$aarticle
000144659 3367_ $$2DataCite$$aOutput Types/Journal article
000144659 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1567169324_2228
000144659 3367_ $$2BibTeX$$aARTICLE
000144659 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000144659 3367_ $$00$$2EndNote$$aJournal Article
000144659 520__ $$aEpigenetic modifications have been shown to play an important role in the classification and pathogenesis of the pediatric brain tumor ependymoma, suggesting they are a potential therapeutic target.Agents targeting epigenetic modifications inhibited the growth and induced the death of ependymoma cells with variable efficiency. However, this was often not at clinically achievable doses. Additionally, DNA methylation profiling revealed a lack of similarity to primary ependymomas suggesting alterations were induced during culture. Toxicity to fetal neural stem cells was also seen at similar drug concentrations.Agents targeting epigenetic modifications were able to inhibit the growth and induced the death of ependymoma cells grown in vitro. However, many agents were only active at high doses, outside clinical ranges, and also resulted in toxicity to normal brain cells. The lack of similarity in DNA methylation profiles between cultured cells and primary ependymomas questions the validity of using in vitro cultured cells for pre-clinical analysis of agents targeting epigenetic mechanisms and suggests further investigation using models that are more appropriate should be undertaken before agents are taken forward for clinical testing.The effects of agents targeting epigenetic modifications on the growth and death of a panel of ependymoma cell lines was investigated, as well as toxicity to normal fetal neural stem cells. The ependymoma cell lines were characterized using DNA methylation profiling.
000144659 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000144659 588__ $$aDataset connected to CrossRef, PubMed,
000144659 7001_ $$aChapman, Rebecca$$b1
000144659 7001_ $$aKings, Holly$$b2
000144659 7001_ $$aAllard, Julie$$b3
000144659 7001_ $$aBarron-Hastings, Jodie$$b4
000144659 7001_ $$0P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aPajtler, Kristian W$$b5$$udkfz
000144659 7001_ $$0P:(DE-He78)45440b44791309bd4b7dbb4f73333f9b$$aSill, Martin$$b6$$udkfz
000144659 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b7$$udkfz
000144659 7001_ $$aGrundy, Richard Guy$$b8
000144659 773__ $$0PERI:(DE-600)2560162-3$$a10.18632/oncotarget.26370$$gVol. 9, no. 92$$n92$$p36530-36541$$tOncoTarget$$v9$$x1949-2553$$y2018
000144659 909CO $$ooai:inrepo02.dkfz.de:144659$$pVDB
000144659 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000144659 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)45440b44791309bd4b7dbb4f73333f9b$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000144659 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000144659 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000144659 9141_ $$y2018
000144659 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000144659 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000144659 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000144659 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000144659 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x0
000144659 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x1
000144659 980__ $$ajournal
000144659 980__ $$aVDB
000144659 980__ $$aI:(DE-He78)B062-20160331
000144659 980__ $$aI:(DE-He78)L101-20160331
000144659 980__ $$aUNRESTRICTED